SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Valiant Laboratories - Quaterly Results

09 Feb 2024 Evaluate
The sales slipped to Rs. 405.15 millions, down -42.75% for the December 2023 quarter as against Rs. 707.74 millions during the year-ago period.The Net Loss for the quarter ended December 2023 is Rs. -35.03 millions as compared to Net Profit of Rs. 76.47 millions of corresponding quarter ended December 2022Operating profit Margin for the quarter ended December 2023 slipped to -45.32% as compared to 107.11% of corresponding quarter ended December 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202312 202212 % Var
Sales 405.15 707.74 -42.75 405.15 707.74 -42.75 405.15 707.74 -42.75
Other Income 17.75 7.84 126.40 17.75 7.84 126.40 17.75 7.84 126.40
PBIDT -45.32 107.11 -142.31 -45.32 107.11 -142.31 -45.32 107.11 -142.31
Interest 0.19 0.40 -52.50 0.19 0.40 -52.50 0.19 0.40 -52.50
PBDT -45.51 106.71 -142.65 -45.51 106.71 -142.65 -45.51 106.71 -142.65
Depreciation 4.94 4.03 22.58 4.94 4.03 22.58 4.94 4.03 22.58
PBT -50.45 102.68 -149.13 -50.45 102.68 -149.13 -50.45 102.68 -149.13
TAX -15.42 26.21 -158.83 -15.42 26.21 -158.83 -15.42 26.21 -158.83
Deferred Tax -2.06 1.21 -270.25 -2.06 1.21 -270.25 -2.06 1.21 -270.25
PAT -35.03 76.47 -145.81 -35.03 76.47 -145.81 -35.03 76.47 -145.81
Equity 434.50 162.80 166.89 434.50 162.80 166.89 434.50 162.80 166.89
PBIDTM(%) -11.19 15.13 -173.91 -11.19 15.13 -173.91 -11.19 15.13 -173.91

Valiant Laboratories Share Price

66.03 -0.97 (-1.45%)
22-Apr-2026 10:50 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1653.80
Dr. Reddys Lab 1215.95
Cipla 1228.20
Zydus Lifesciences 927.75
Lupin 2307.30
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×